Articles related to CLINICAL TRIALS

Amid emerging safety concerns, ADC Therapeutics has paused its mid-stage trial of Zynlonta, a potential game-changer in treating certain types of blood cancer, calling into question the drug’s future trajectory.

Orforglipron is a novel once-daily oral GLP-1 receptor agonist that has been shown to be effective in reducing weight in adults with obesity or overweight. Further studies are needed to establish whether the health benefits seen with injectable GLP-1 receptor agonists are shared by orforglipron.

A new study suggests that vitamin D supplementation may reduce the risk of major cardiovascular events in older adults. The findings of this study warrant further investigation to determine the optimal dose and duration of vitamin D supplementation for cardiovascular disease prevention.

Gadoquatrane, a promising GBCA, enters Phase 3 clinical testing, potentially offering safer MRI procedures and advancing diagnostic capabilities for patients with CNS disorders, including MS.

Discover the potential of pirtobrutinib, a noncovalent BTK inhibitor, in transforming the management of refractory B-cell cancers. Explore the promising results from the recent phase 1-2 trial.

Explore the novel findings of a phase 2 trial on the tri-agonist retatrutide, demonstrating substantial weight reductions in adults with obesity over a 48-week period.